A study testing whether a GLP-1 and GIP medicine, tirzepatide, can help people reduce liver fat.

Recruiting now. Registry record last updated December 23, 2025.

Who can join: Adults 18 to 70, have liver cirrhosis, BMI 35+.
What you take: Tirzepatide, given as part of the study. Check ClinicalTrials.gov for this trial's study groups, including any placebo or comparison medicine.
How long it lasts: The full study runs about 8 years.
What you get: Costs vary by study. Ask the study team what this one covers, including the study medicine, visits and travel, before you sign the consent form.

This one may not fit you. We check your age, where you live, and the rules each study sets, then show the clinical trials that do.

Check my fit →

Phase Phase 4Sponsor The Cleveland ClinicDrug tirzepatideClass GLP-1/GIPSites 1 USEnrollment target 70

What this study is for

Primary condition: Liver Cirrhoses. Also studied in: Portal Hypertension Related to Cirrhosis, Severe Obesity, TIPS.

Full scientific study title: Optimizing Portal Hypertension With TIPS and Interval Metabolic Surgery for Advanced Liver Disease.

Who can join

Age18 to 70SexAnyBMI35 to 70

Adults 18 to 70, have liver cirrhosis, BMI 35+. A site coordinator confirms whether you qualify during a free screening visit. The exact medical requirements are below.

Full medical eligibility (for you and your doctor)verbatim from the registry

This is the exact wording from ClinicalTrials.gov, including clinical measures (lab values, imaging scores). Bring it to your doctor if any of it is unclear.

Key inclusion criteria

Candidate for general anesthesia.
Age 18-70 years at consent.
BMI 35-70 kg/m² at first study visit.
Eligible for sleeve gastrectomy per ASMBS/IFSO 2022 guidelines.
Insurance coverage for metabolic surgery.

Key exclusion criteria

Prior bariatric/metabolic surgery (except removed devices ≥ 3 months earlier).
Prior complex foregut surgery.
History of solid-organ transplant.
Severe pulmonary disease (FEV1 \< 50 % predicted).
Significant cardiac or atherosclerotic disease with planned re-vascularization within 12 months.

Where this trial is enrolling

This trial has 1 sites across 1 state. Contact a site coordinator directly to start screening.

Ohio1 site

Cleveland Clinic Main Campus
Cleveland, Ohio
Awwab F Hammad, MD+1 216 444 5022hammada4@ccf.org

Follow this trial

We email you if NCT07058155 changes status, adds new sites in your state, or if a similar trial opens for the same condition.

Timeline

Started enrolling: December 17, 2025. Expected completion: February 1, 2034. Last updated on ClinicalTrials.gov: December 23, 2025.

Official source

Every Monday we check this trial against ClinicalTrials.gov, the federal registry for clinical research. Last checked September 4, 2026. Confirm the current status there before you contact a site:

View on ClinicalTrials.gov →

Back to the full directory → or take the matching quiz if you want clinical trials filtered to your conditions and location.

John Samaras, Founder and EditorI started GLP Chart after overpaying for a GLP-1 myself. Based in Austin, Texas.
About this site LinkedIn Contact

Why you can trust GLP Chart. Same scoring framework applied to every program. No paid placements. We never remove unfavorable information at an advertiser's request. Pricing is pulled from each program's public-facing page every Monday.